Lacosamide is a prescription medication used to treat partial-onset seizures in adults with epilepsy [3]. As with any medication, there are precautions to take when prescribing lacosamide.

Firstly, it is important to note that lacosamide is a controlled substance and should be prescribed and dispensed with caution [2]. It is classified as a Schedule V controlled substance by the Drug Enforcement Administration (DEA) [1]. This means that it has a low potential for abuse relative to other controlled substances, but it still has the potential for abuse and dependence.

Secondly, lacosamide has been associated with serious adverse reactions, including cardiac arrhythmias, syncope, and increased risk of suicidal thoughts and behavior [2]. Therefore, it is important to monitor patients for any signs of these adverse reactions while they are taking lacosamide.

Thirdly, lacosamide may interact with other medications that a patient is taking. For example, it may increase the risk of adverse reactions when taken with other medications that affect the heart, such as beta-blockers or calcium channel blockers [3]. Therefore, it is important to review a patient's medication history and current medications before prescribing lacosamide.

Lastly, lacosamide should be used with caution in patients with liver or kidney disease, as it is metabolized in the liver and excreted by the kidneys [3]. Dose adjustments may be necessary in these patients to avoid adverse reactions.

In conclusion, when prescribing lacosamide, it is important to be aware of its potential for abuse and dependence, monitor patients for adverse reactions, review medication history, and use caution in patients with liver or kidney disease. By taking these precautions, healthcare providers can help ensure the safe and effective use of lacosamide in patients with epilepsy.

Sources:
[1] DrugPatentWatch. Lacosamide. Retrieved from https://www.drugpatentwatch.com/p/tradename/LACOSAMIDE
[2] U.S. Food and Drug Administration. (2022). Vimpat (lacosamide) tablets and injection, for intravenous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022253s055,022254s045,022255s037lbl.pdf
[3] MedlinePlus. Lacosamide. Retrieved from https://medlineplus.gov/druginfo/meds/a609028.html